Pharmacopoeial impurityMilbemycin EP Impurity ECat. No. P-M129-002CAS 86691-97-6Family · Pharmaceutical analytical standards
Milbemycin
A family of antiparasitic macrolides related to the avermectins, first isolated in 1972 from the bacterium Streptomyces hygroscopicus: they open glutamate-sensitive chloride channels in invertebrates and are used in veterinary medicine against worms, ticks and fleas. This family brings together pharmacopoeial impurities and other impurities.
Did you know?Industrial fermentation yields far less of them than of the avermectins: in 2017 researchers swapped part of the genes and persuaded the avermectin bacterium, Streptomyces avermitilis, to make milbemycin instead.
Pharmacopoeial impurityMilbemycin EP Impurity ECat. No. P-M129-002CAS 86691-97-6
Pharmacopoeial impurityMilbemycin EP Impurity FCat. No. P-M129-003CAS 86691-98-7
Pharmacopoeial impurityMilbemycin EP Impurity GCat. No. P-M129-004CAS 93074-02-3
ImpurityMilbemectin A4Cat. No. P-M129-005CAS 51596-11-3
ImpurityMilbemycin A3 OximeCat. No. P-M129-006CAS 114177-14-9
ImpurityMilbemycin A4 OximeCat. No. P-M129-007CAS 93074-04-5
ImpurityMilbemycin B1Cat. No. P-M129-008CAS 1627519-87-2
ImpurityMilbemycin B2Cat. No. P-M129-009CAS 1627519-88-3
ImpurityMilbemycin DCat. No. P-M129-010CAS 77855-81-3
ImpurityMilbemycin Impurity 1Cat. No. P-M129-011
ImpurityMilbemycin EP Impurity HCat. No. P-M129-012CAS 1025877-03-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.